Objective: This study aims to develop a Vulvovaginal Symptoms Questionnaire (VSQ) to determine the symptoms, emotions, life impact, and sexual impact of vulvovaginal symptoms on postmenopausal women.
V ulvovaginal atrophy and related vulvovaginal symptoms represent a unique and understudied constellation of symptoms in postmenopausal women. Postmenopausal vulvovaginal symptoms include dryness, burning, pruritus, and dyspareunia. 1, 2 Vulvovaginal symptoms are common and have been reported by 9.6% to 44.4% of postmenopausal women. 2<4 To date, there has been limited information on the impact of vulvovaginal symptoms on the lives of postmenopausal women.
Currently, a validated instrument for measuring vulvovaginal symptoms and disease-specific quality of life in postmenopausal women is not available. 5 In the absence of a disease-specific quality-of-life questionnaire, many trials measuring the efficacy of vaginal estrogen therapy have used the most bothersome symptom approach. 6<8 A validated scale for eliciting vulvovaginal symptoms and quantifying life impact on postmenopausal women is necessary to allow for future studies in response to treatments for these symptoms. The purpose of this study was to develop a Vulvovaginal Symptoms Questionnaire (VSQ) to study the symptoms, emotions, life impact, and sexual impact of vulvovaginal symptoms on postmenopausal women.
METHODS

Preliminary questionnaire development
Approval was obtained from the Institutional Review Board at Yale University. We developed a preliminary questionnaire that focuses on vulvovaginal symptoms based on modifications to Skindex-16Va validated questionnaire for measuring the impact of skin disease symptoms on quality of life and an instrument written in English. 9, 10 Specifically, Byour skin condition[ in Skindex-16 was changed to Byour vulva[ for the VSQ. Input from an expert panel of three gynecologists, a dermatologist, and an expert in survey methodology was used to add additional questions specifically related to vulvovaginal symptoms. We added questions to explore specific vulvovaginal concerns (eg, odor and discharge), as well as a domain of questions regarding sexual function. As in the original Skindex-16, each question was asked in the form of BDuring the past week, how often have you been bothered by [ To test the face validity of these developed questions, we held face-to-face Bthink-aloud[ cognitive interviews with five postmenopausal women seeking routine gynecologic care. These interviews further explored the pertinence and quality of both questions and responses. These interviews confirmed that all pertinent issues related to vulvovaginal symptoms were covered and that women understood the questions.
Study population
We recruited postmenopausal women seeking routine gynecologic care at a general gynecology practice and at a gynecology practice serving women seeking treatment of pelvic floor disorders. Participants were excluded if they had known vulvar dermatoses, including lichen sclerosus, lichen planus, psoriasis, Beh0et's disease, hidradenitis suppurativa, anorectal Crohn's disease, or herpes simplex virus. Participants were also excluded if they required immediate treatment of vulvovaginal symptoms.
Test-retest reliability
Test-retest reliability was assessed by asking the women to fill out the VSQ approximately 2 to 4 weeks after their initial recruitment in this study. The second VSQ was given to women with a self-addressed stamped envelope at the conclusion of the initial recruitment visit with instructions to complete and return it in 2 to 4 weeks by mail. This interval was chosen to allow enough time to pass between the time that the women completed the original VSQ and the retest to avoid rote recall of questions. If the second VSQ was not received in 3 weeks, one reminder postcard was mailed and two reminder telephone calls were placed. Women who were diagnosed with active Candida vulvovaginitis at the time of initial enrollment were treated and excluded from the test-retest analysis. The test-retest reliability for individual questions was measured using J coefficients (e0.4, poor; 0.41-0.60, moderate; 0.61-0.80, substantial; 90.80, almost perfect). 11 The test-retest reliability for the sum score of the different scales (symptoms, emotion, life impact, and sexual impact) was assessed with intraclass coefficients (ICCs) (e0.4, poor; 0.41-0.60, moderate; 0.61-0.80, good; 90.80, excellent) using a random-effects analysis of variance mixed model. 12 
Construct validity
Construct validity is demonstrated by testing a new instrument against a gold standard. There is currently no gold standard for the assessment of vulvovaginal skin symptoms in older women. 5, 13 This presented a challenge in establishing the construct validity of the VSQ. In the absence of a gold standard, we compared the VSQ to other disease-specific quality-of-life instruments measuring the symptom bother and life impact of common gynecologic disorders on postmenopausal women. We hypothesized that women with increased bother from other gynecologic conditions, such as pelvic floor disorders and sexual dysfunction, would have increased vulvovaginal symptom bother. We expected fair correlations between other disease-specific quality-of-life questionnaires in gynecology and the VSQ. We measured disease-specific bother from two validated questionnaires for female pelvic floor disorders: the Pelvic Floor Distress Inventory-20 (PFDI-20) and the Pelvic Floor Impact Questionnaire-7 (PFIQ-7). 14 Increased scores on the PFDI-20 and the PFIQ-7 indicate increased symptom bother from female pelvic floor disorders. We further tested the correlation of the VSQ with two sexual function questionnaires: the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) and the Female Sexual Function Index (FSFI). 15, 16 Construct validity of the VSQ was tested by using the Spearman-Brown correlation coefficient (Q) to compare the VSQ with the PFDI-20, the Pelvic Floor Impact Questionnaire-21, the PISQ-12, and the FSFI. Correlations of 0 G |Q| e 0.25 were considered low, whereas correlations of 0.25 G |Q| e 0.5 were considered fair. 17 To further test the construct validity of the VSQ, we performed a comprehensive vulvar examination that included vulvar sensory testing to measure vulvar pain, as well as vaginal maturation index and vaginal pH to measure vulvovaginal atrophy. 7, 8 Comprehensive vulvar examinations were conducted by board-certified gynecologists. These examinations included visual inspection of the vulva and the vagina (to evaluate skin changes and possible vulvar intraepithelial neoplasia), normal saline preparation of vaginal secretions (to evaluate infectious vaginitis), potassium hydroxide (KOH) preparation (to evaluate current vulvovaginal candidiasis), yeast culture if indicated (to confirm current vulvovaginal candidiasis), and pH assessment of vaginal secretions. Vulvar sensory testing using a cotton swab (cotton swab testing) classified 23 areas around the vulva as free of discomfort (0), with mild discomfort (1), with moderate discomfort (2), or with severe discomfort (3), for a total score ranging from 0 (symptom-free in all areas) to 69 (severe discomfort in all areas). 18, 19 Vulvar sensory testing scores were not normally distributed; therefore, the Spearman-Brown correlation coefficient was used to compare the VSQ with vulvar sensory testing scores. The vaginal maturation index was obtained for all women in the manner described by Freedman et al. 8 Vaginal maturation index scores range between 0 and 1, with 1 indicating greater atrophic vaginitis.
Logical consistency
To test whether women were answering questions with logical consistency, we divided women into two groups: women who reported having one or more of seven vulvovaginal symptoms (itching, burning, hurting, irritation, dryness, discharge, and odor) and women who denied any symptoms. Women's responses to the emotions and life impact scales were examined with the expectation that women without vulvovaginal symptoms would not report any emotional or life impact.
Confirmatory factor analysis
Skindex-16 has three distinct scales: symptoms, emotions, and functioning. In developing the VSQ, four distinct a priori scales of the VSQ were developed: symptoms, emotions, life impact, and sexual impact. Confirmatory factor analysis was performed to verify the four a priori scales of the VSQ using Mplus software (Muthen&Muthen, Los Angeles, CA). Confirmatory factor analysis was performed twice because only 75 of 120 women reported being sexually active and completed the sexual impact scale of the VSQ. First, we performed confirmatory factor analysis modeling on all 120 women (regardless of current sexual activity) for the first three scales of the VSQ (symptoms, emotions, and life impact). Next, we performed confirmatory factor modeling, including all four scales (symptoms, emotions, life impact, and sexual impact) of the VSQ, on the 75 women with complete data. The goodness of fit of the confirmatory factor analysis models was evaluated using the following indices (cutoff levels): comparative fit index (Q0.95), Tucker Lewis index (Q0.95), root mean square error of approximation (G0.1), and weighted root mean square residual (G0.9). 20<22
Internal consistency
After confirming the distinct scales of the VSQ to be symptoms, emotions, life impact, and sexual impact, we assessed the internal consistency of the questions by calculating the Cronbach's > coefficient.
Sample size
For factor analysis, a sample size between 50 and 250 participants was recommended as adequate, with most authors recommending at least 100 participants. 23<25 We recruited 120 women to account for attrition. All data analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC), unless otherwise specified. For parametric data, Fisher's exact test, Student's t test, and W 2 test were used as appropriate. For nonparametric data, Wilcoxon rank sum test was used as appropriate.
RESULTS
Study population
One hundred twenty postmenopausal women participated in the psychometric validation of the VSQ. The mean (SD) age was 66.3 (10.9) years, and ages ranged from 48 to 91 years. Most women identified their race/ethnicity as non-Hispanic white (91.7%). Black women represented 2.5% of the cohort, and Hispanic women represented 2.5% of the cohort. Ten women (8.3%) reported current use of systemic estrogen therapy, and 35 women (29.2%) reported current use of vaginal estrogen. Seventy-five women (62.5%) reported currently being sexually active with a partner (Table 1) .
Questionnaire
All 120 women were able to complete the VSQ without assistance. More than 99% of questions had complete data. Ninety-nine women (82.5%) reported having at least one of the seven vulvovaginal symptoms in the last week ( Table 2) .
Test-retest reliability
Three women were diagnosed with active Candida vulvovaginitis, treated, and excluded from test-retest reliability testing. Ninety-one of 117 women (77.8%) completed and returned the second VSQ within 4 weeks. Ninety percent (19/21) of individual items had J values higher than 0.41, indicating moderate reliability ( Table 3 ). The test-retest reliability for the scores of the four scales was measured using ICC (0.75, 0.60, 0.55, and 0.65 for symptoms, emotions, life impact, and sexual impact, respectively).
Construct validity
The Spearman-Brown correlations of the VSQ with other disease-specific quality-of-life questionnaires were 0.41 for the PFDI-20 (measuring pelvic floor symptom distress), 0.45 for the PFIQ-7 (measuring pelvic floor life impact), and 0.42 for the PISQ-12 (measuring sexual function; Table 4 ). The Spearman-Brown correlation coefficient for the VSQ with the FSFI was j0.16. 
Comprehensive vulvar examination
Three of 99 women who reported vulvar symptoms were diagnosed as having active Candida vulvovaginitis based on KOH testing and as confirmed with yeast culture. All three women diagnosed with active Candida infections reported vulvovaginal symptoms. Vulvar sensory testing scores were significantly higher in women with symptoms (n = 99) than in women without symptoms (n = 21): median (interquartile range), 0 (0-4) versus 0 (0-1), P = 0.02 ( Table 1) . The Spearman-Brown correlation coefficient of the VSQ compared with the vulvar sensory testing scores was 0.36. We analyzed three individual symptoms on the VSQ (burning, hurting, and irritation) with vulvar sensory testing scores. Women who reported vulvar burning or stinging had a higher median (interquartile range) vulvar sensory testing score compared with women who did not report burning or stinging: 2 (0-9) versus 0 (0-1), P G 0.001. Women who reported hurting had a higher median (interquartile range) vulvar sensory testing score compared with women who did not report hurting: 2 (0-12) versus 0 (0-2), P = 0.002. Women who reported being irritated had a higher median (interquartile range) vulvar sensory testing score compared with women who did not report being irritated: 1 (0-6) versus 0 (0-1), 
Logical consistency
Among 21 women who reported no vulvovaginal skin symptoms, none reported any emotional impact, life impact, or sexual impact of vulvovaginal symptoms.
Confirmatory factor analysis
Confirmatory factor analysis modeling was performed with answer choices for the emotions and life impact scales from all 120 women. When we performed confirmatory factor analysis on the original continuous responses, the goodness of fit of the model was not confirmed. When the responses were converted from a continuous scale into a dichotomous response of no bother versus any bother, the goodness of fit of the confirmatory factor analysis model was confirmed. 18<20 The indices of confirmatory factor analyses that confirmed model fit were as follows: comparative fit index, 0.98; Tucker Lewis index, 0.99; root mean square error of approximation, 0.07; weighted root mean square residual, 0.82. The second confirmatory factor analysis model, including the sexual impact scale that was completed by 75 women who reported current sexual activity, was performed. The indices of confirmatory factor analyses that confirmed model fit including all four scales (symptoms, emotions, life impact, and sexual impact) were as follows: comparative fit index, 0.97; Tucker Lewis index, 0.98; root mean square error of approximation, 0.09. The weighted root mean square residual was 0.97. Although the weighted root mean square residual was higher than the cutoff level (G0.9), the factor structure of the four scales was not ruled out by the indices of fit.
Internal consistency
Cronbach's > coefficient was calculated to determine the internal consistency of the four scales (symptoms, emotions, life impact, and sexual impact). The Cronbach's > coefficients were 0.76, 0.87, 0.83, and 0.82 for the symptoms, emotions, life impact, and sexual impact scales, respectively ( Table 5 ).
DISCUSSION
The VSQ is a questionnaire designed to measure the disease-specific quality-of-life impact of vulvovaginal symptoms on postmenopausal women. To date, there has been limited information on the presence of vulvovaginal symptoms in postmenopausal women and their impact on quality of life. As standardized methods for evaluating these symptoms are developed, our understanding of prevalence and life impact will progress.
In the absence of a gold standard for the quantification of vulvovaginal symptoms and life impact, we have tested the validity of the VSQ with other validated gynecologic questionnaires and physical examination findings. We based our instrument for measuring vulvovaginal symptoms on Skindex-16. Skindex has been adapted and used in the study of numerous skin conditions, including psoriasis, atopic dermatitis, and leg ulcers. 26 Skindex has also been used to study the life impact of vulvodynia on women. 27 The flexibility of Skindex in studying the life impact of many skin conditions made this the ideal instrument on which to base our questions. We demonstrated fair correlations between the VSQ and other questionnaires measuring other gynecologic diseases in older women, namely, the PFDI-20 and the PFIQ-7. We also demonstrated a fair correlation between the PISQ-12 (a validated instrument for studying sexual function in women with pelvic floor disorders) and the VSQ. However, we found a low correlation between the FSFI and the VSQ. This may be attributed to the different focus of the FSFI on six different aspects of sexual function (desire, arousal, lubrication, orgasm, satisfaction, and pain), whereas the VSQ focuses on pain, bleeding, and dryness with intercourse. 16 In addition, we assessed vulvar discomfort with cotton swab testing and found a 0.36 correlation between cotton swab testing scores and VSQ scores. Cotton swab testing scores are dependent on a woman's report of mild, moderate, or severe pain when each location on the vulva is touched. Pain can be present even when no visual abnormalities are observed, which is probably why we observed a fair correlation between the cotton swab testing and the VSQ. Consistent with the original Skindex, a woman's report of skin symptoms was not consistently related to a visual observation of physical examination findings. 28 Although there were no women with significant visual physical examination findings without symptoms, many women reported symptoms without physical examination findings.
We diagnosed active Candida vulvovaginitis by (1) symptoms, (2) KOH preparation, and (3) yeast culture; however, we did not use polymerase chain reaction. Recently, polymerase chain reaction has been demonstrated to be a more sensitive method for diagnosing vulvovaginal candidiasis in women with a diagnosis of recurrent vulvovaginal candidiasis. 29 We found the test-retest reliability of the VSQ to be adequate 2 to 4 weeks after the women initially completed the VSQ. Because skin symptoms are dynamic and the VSQ asks about symptoms Bin the past week,[ it is possible that women's vulvovaginal symptoms changed during the time interval from the initial completion of the VSQ to the second time they completed the questionnaire. Other validated measures of general skin symptoms (not specific for vulvovaginal symptoms) have reduced the time interval for measuring test-retest reliability to 72 hours. 9, 28 We did have lower J and ICC values than reported on the psychometric testing of Skindex-16. This can probably be attributed to our choice of a longer time interval between the completion of the initial VSQ and the completion of the follow-up VSQ. This research is limited by the population of women studied. Women were recruited at gynecology practices. Women seeking routine gynecologic care are probably more bothered by gynecologic conditions and probably have a higher prevalence of vulvovaginal symptoms than women who do not seek gynecologic care. We hypothesize that the true prevalence of vulvovaginal symptoms in all postmenopausal women is lower than that observed in this current study population. However, studying the VSQ in a population of women with a high prevalence of vulvovaginal symptoms allowed us to demonstrate the psychometric properties of the VSQ. In addition, we tested the VSQ for face validity among five women seek routine gynecologic care. Further testing of face validity may be necessary among different populations (eg, postmenopausal women not seeking medical care).
Future studies are needed to determine whether dichotomous responses are truly the best answer choices for evaluating these symptoms. In using a Likert scale consistent with the original phrasing of Skindex-16, women were asked about frequency (BHow often have you been bothered?[), but not about severity. Future studies will determine if severity of bother (BHow much?[) might be a preferred question/response pair over the current dichotomous responses (yes/no). Authors have advocated analyzing the most bothersome symptom, in addition to recording the presence of vulvar symptoms, in the study of treatments for vulvovaginal atrophy. 6 We believe that exploring the frequency and the severity of vulvovaginal symptom bother is important, and we expect future research to demonstrate that severity of bother is the most informative answer choice for the VSQ. In addition to asking about the most bothersome symptom, we concur with Simpson and Murphy 5 that quality-of-life impact from vulvovaginal symptoms also needs to be explored, which is why the VSQ includes the emotional, life impact, and sexual impact scales. Finally, we demonstrated that postmenopausal women without symptoms did not have emotional or life impact; therefore, we propose that women who answer Bno[ to the first seven symptom questions do not need to complete the remaining three scales of the VSQ.
CONCLUSIONS
The VSQ is a reliable and internally consistent instrument for measuring vulvovaginal symptoms in postmenopausal women. We have demonstrated a reasonable validity of the VSQ in the absence of a gold standard for measuring vulvovaginal symptoms. We recognize that the three psychometric properties of a good questionnaire are validity, reliability, and sensitivity to change. In this first study, we have demonstrated the psychometric properties of validity and reliability. As we develop this questionnaire to include clinical implications, the responsiveness (or sensitivity to change) of the VSQ to symptoms and to the life impact of treatments will be tested in future investigations. The final step in this instrument's development will be defining a minimally important difference of change in this scale that reflects a clinically meaningful difference in a woman's life to confirm that the VSQ can measure the impact of clinical treatment.
